Spokane's roughly five-point obesity gap over Washington, the March 4, 2026 HPSA designations covering most of the county, a fully price-opaque local market, and Apple Health's narrow coverage.
Spokane's adult obesity rate is 35.3% (BRFSS 2023, CDC PLACES) 1 against Washington's statewide 30.6% the same year 3, an almost five-point gap in a state not usually associated with high obesity. Spokane County's own rate, 34.7% 2, is nearly the same as the city's, so the real comparison here is city versus state, not city versus county.
In a city of 230,609 inside a metro of 604,962, with a median household income of $78,583 and 6.3% uninsured 4567, the local access story changed in March 2026.
Per HRSA's Health Workforce Shortage Areas Dashboard, data as of 2026/08/26 and pulled 2026/08/27, HRSA designated three Primary Care HPSAs blanketing Spokane on the same day, 3/4/2026: the City of Spokane Service Area as a Low-Income Population HPSA (score 16/25, covered population 62,132), NE Spokane County as a Geographic Area HPSA (score 15/25, population 247,086), and SW Spokane County as a Geographic Area HPSA (score 15/25, population 106,911) 89.
That sits on top of already-severe facility-level shortages across Spokane's safety-net system: Community Health Association of Spokane (FQHC, score 19/25, designated 2003), The NATIVE Project (FQHC and Urban Indian Health Organization, score 20/25, designated 2010), and Camas Path Behavioral Health (Indian Health Service, score 17/25, designated 2019). Three older county-level geographic HPSAs covering North, Southeast, and Southwest Spokane County, all originally designated 2017, are currently listed Proposed For Withdrawal pending HRSA's 2027 Federal Register review following the Sept. 2025 National Shortage Designation Update, so not everything on the books is newly active. Mental Health HPSAs separately cover North Spokane, SE Spokane, and City of Spokane low-income and homeless-population service areas, designated Oct. 2025 through Mar. 2026 with scores of 16 to 19 8. Net effect: nearly the entire county's population now sits inside a federally recognized primary-care shortage zone.
On the insurance side, Washington's Apple Health, administered by the state Health Care Authority, does not cover Wegovy (semaglutide) or Zepbound (tirzepatide) for obesity or weight loss as a standalone indication, per WAC 182-530-2100(1)(b)(i) and 42 U.S.C. 1396r-8(d)(2)(A). Wegovy is covered under HCA Medical Policy 61.25.20.AA-4, effective 2/1/2026, only for patients with established cardiovascular disease and obesity or overweight at elevated MACE risk (BMI ≥27, per the SELECT trial) or moderate-to-severe MASH; Zepbound is covered under HCA Medical Policy 61.25.25.AA-1, effective 5/1/2025, only for moderate-to-severe obstructive sleep apnea with obesity (BMI ≥30). Obesity alone does not qualify under either policy 101112.
The absence is the finding: no Spokane clinic could be confirmed publishing its own GLP-1 price this review. What was checked, and came back without a published price, includes MultiCare Rockwood Clinic weight-management, Providence weight-management Spokane, Restore Hyper Wellness Spokane, and Ideal Image Spokane, plus a business-registry sweep that surfaced only Bloom Aesthetics and a generic Dynamic Weight Loss listing, neither with pricing.
One number circulates locally and is worth labeling rather than repeating as fact: Trimi Health's own blog claims unnamed Spokane clinics run $300 to $600 per month. That is unverified competitor color, not a citation, and it is not used as a fact here 13.
Astra's price is national and flat: $68/month semaglutide and $118/month tirzepatide on 12-month plans, billed annually at $816 and $1,416, the same price in Spokane as on every other Astra city page.
HRSA's framework scores only primary care, dental, and mental health, so there is no federal obesity-medicine or endocrinology-specific shortage designation, and no dataset directly measures bariatric or endocrinology wait times or specialist counts in Spokane. That is a data gap, stated as one 8.
What the HPSA data does show is that Spokane's safety-net primary-care system already carries some of the highest severity scores available, Community Health Association of Spokane at 19/25 and The NATIVE Project at 20/25, both Designated, and that as of March 2026 new geographic HPSAs blanket essentially the entire county population 8. Since a referral for GLP-1 therapy typically starts with a primary-care visit, the front door most Spokane residents would use to reach a weight-management specialist is itself under federally recognized strain county-wide; the constraint sits upstream of specialist supply.
A telehealth consult skips that front door entirely: evaluation, prescription, and shipping without a primary-care appointment first. See the Washington GLP-1 overview for statewide policy.
Astra treats patients in Washington through state-licensed physicians.
We could not confirm a Spokane clinic that publishes its own GLP-1 pricing online as of this review (checked local hospital-system weight-management programs and med-spa/wellness listings). One national telehealth competitor's blog cites unnamed Spokane clinics charging $300-$600/month, but that figure names no provider and isn't independently verifiable, so we don't use it as a comparison. What we can say with certainty: Astra's price is flat and public nationwide — $68/month for semaglutide and $118/month for tirzepatide, billed annually ($816/$1,416 per year) — the same in Spokane as everywhere else Astra serves.
Astra charges the same nationwide price in Spokane as in every other city it serves: $68/month for semaglutide and $118/month for tirzepatide, each on a 12-month plan billed annually ($816 and $1,416/year). No Spokane clinic could be confirmed publishing a comparable local price this review cycle.
Spokane's adult obesity rate is 35.3% (BRFSS 2023, CDC PLACES), versus Washington's statewide rate of 30.6% the same year — a nearly 5-point gap. Spokane County's rate (34.7%, BRFSS 2023) is almost identical to the city figure, so this is a state-level gap, not a county-level one.
Not for weight loss alone. Per HCA's published drug-coverage criteria, Apple Health covers Wegovy (semaglutide) only for patients with established cardiovascular disease and obesity/overweight at elevated cardiovascular-event risk, or moderate-to-severe MASH; it covers Zepbound (tirzepatide) only for moderate-to-severe obstructive sleep apnea with obesity. Obesity by itself is not a covered indication under either policy.
Yes. Astra is licensed to serve patients in all 50 states, including Washington, with online consultations and prescriptions shipped directly — useful in Spokane, where new HRSA primary-care shortage designations (March 2026) now cover nearly the entire county's population, making a fast visit with your own doctor harder to get right when it matters most.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.